New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 22, 2014
07:06 EDTISISIsis Pharmaceuticals' ISIS-FXI shows positive Phase 2 data
Isis Pharmaceuticals announced positive top-line data from a Phase 2 comparator-controlled study evaluating the incidence of venous thrombolic events in patients treated with ISIS-FXIRx undergoing total knee replacement surgery, or total knee arthroplasty. ISIS-FXIRx inhibits the production of Factor XI, a coagulation factor that plays a key role in thrombosis. Patients treated with 300 mg of ISIS-FXIRx experienced a seven-fold lower incidence of VTEs compared to patients treated with enoxaparin. Patients treated with 200 mg of ISIS-FXIRx had comparable incidence of VTEs compared to patients treated with enoxaparin. .
News For ISIS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 26, 2015
10:10 EDTISISAnalyst calls sharp pullback in biotech stocks 'misguided'
Subscribe for More Information
06:45 EDTISISBiotech valuation concerns 'misguided,' says Piper Jaffray
Subscribe for More Information
March 23, 2015
07:04 EDTISISIsis Pharmaceuticals says ISIS-ANGPTL3Rx 'well tolerated' in Phase 1 study
Isis Pharmaceuticals announced positive results from a Phase 1 study with ISIS-ANGPTL3Rx. In this study, healthy volunteers treated with ISIS-ANGPTL3Rx achieved dose-dependent, statistically significant reductions in angiopoietin-like 3 of up to 93% with a mean reduction of up to 84% from baseline. In addition, statistically significant reductions from baseline in lipid parameters were observed, including up to 63% with a mean reduction of up to 49% in triglycerides and up to 46% with a mean reduction of up to 28% in total cholesterol. ANGPTL3 is a protein that acts as a key regulator of these blood lipids. These data were presented at the 83rd European Atherosclerosis Society in Glasgow, United Kingdom. The Phase 1 study of ISIS-ANGPTL3Rx was a blinded, placebo-controlled, dose-escalation study in healthy volunteers. The study was designed to assess the safety, tolerability and pharmacokinetics of ISIS-ANGPTL3Rx. ISIS-ANGPTL3Rx was evaluated in single and multiple doses ranging from 50 mg per week up to 400 mg per week for the single dose and 100 mg per week up to 400 mg per week for the multiple dose. In this study, ISIS-ANGPTL3Rx was generally well tolerated.
March 20, 2015
11:45 EDTISISIsis Pharmaceuticals management to meet with Needham
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use